DESTINY Breast05/ TruDy (GBG103)

T-DXd vs. T-DM1 in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy
(DESTINY-Breast05; NSABP B-60; GBG-103; SOLTI-2001.NCT04622319 )

  1. Startseite
  2. Studien
  3. DESTINY Breast05/ TruDy


A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05)

Trial overview was presented at the GBG annual meeting 2021.See the video online or download the slides here.


Trials is open for recruting.



Dr. Ioannis Gkantiragas

Viktoria Tierbach

+49 6102 7480-440